Sandoz Group

Sandoz Group Enterprise Value

The Enterprise Value (EV) of Sandoz Group (SDZ.SW) as of Oct 27, 2026 is 41.47 B USD. In the previous year, Enterprise Value (EV) was 41.98 B USD — a change of -1.20% (lower).

Enterprise Value

41.47 BUSD

YoY

-1.20%

Last updated:

Enterprise Value (EV) of Sandoz Group is 2025 41.47 B USD. Enterprise Value (EV) of Sandoz Group was 2024 41.98 B USD. It decreases by -1.20% lower compared to the previous year.

The Sandoz Group Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2020
37.79 B USD
Jan 1, 2021
37.78 B USD
Jan 1, 2022
37.84 B USD
Jan 1, 2023
41.93 B USD
Jan 1, 2024
41.98 B USD
Jan 1, 2025
41.47 B USD
The Sandoz Group Enterprise Value history
YEAREnterprise ValueYoY
41.47 BUSD-1.20%
41.98 BUSD+0.12%
41.93 BUSD+10.81%
37.84 BUSD+0.16%
37.78 BUSD-0.04%
37.79 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sandoz Group Stock analysis

What does Sandoz Group do? Sandoz Group AG generates revenue through its Generics and Biosimilars businesses. The Generics business develops, manufactures, and markets active ingredients and finished dosage forms of small molecule pharmaceuticals, as well as anti-infective finished dosage forms and active pharmaceutical ingredients. The Biosimilars business develops, manufactures, and markets protein-based biological products similar to already approved biological medicines. Sandoz serves customers worldwide across therapeutic areas including cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory treatments. Its product portfolio covers all major treatment areas for patient care. The company's Generics business focuses on small molecule pharmaceuticals and anti-infectives, while Biosimilars targets protein-based biological products. Both segments serve global healthcare markets with products for various therapeutic areas. Sandoz's customers are healthcare providers and institutions worldwide that require pharmaceutical solutions for diverse medical conditions. Sandoz Group AG's revenue streams come from the sale of generics and biosimilars across all therapeutic areas. The company's products are distributed globally to healthcare systems and providers who treat patients in cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory conditions. The firm's business model relies on developing and commercializing both small molecule pharmaceuticals and biological products to meet global healthcare needs. Sandoz Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sandoz Group stock

Enterprise Value (EV) of Sandoz Group is 41.47 B USD in 2025.

Enterprise Value (EV) of Sandoz Group changed from 41.98 B USD to 41.47 B USD, representing a -1.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Sandoz Group since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Sandoz Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Sandoz Group

All Key Metrics — Sandoz Group